Business Wire

Earnix Survey Reveals Majority of Insurers Plan to Implement AI Predictive Models Within Two Years

4.11.2024 18:10:00 EET | Business Wire | Press release

Share

Earnix, the leading AI, real-time platform for intelligent decisioning SaaS solutions for the insurance and financial services industries, today announced its third annual survey on the state of the insurance market, the 2024 Industry Trends Report. The survey of over 400 global insurance executives uncovers key findings, trends, implications for what’s next in insurance, and sheds light on the role technology can play in shaping a better future.

Key findings from the 2024 survey include:

  • More than two-thirds (70%) of respondents expect to deploy AI models that make predictions based on real-time data in the next two years
  • More than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year
  • 58% of respondents take more than 5 months to implement a rule change and 21% take longer than 7 months
  • Insurers still need to move beyond legacy systems and fully modernize their operations, yet 49% admit they are behind schedule

“This year’s survey reveals the rapid use of AI, a 5–7-month average deployment of rule changes, as well as struggles with modernization,” said Robin Gilthorpe, CEO of Earnix. “Macroeconomic conditions such as inflation, climate change, cybersecurity risk, and uncertain economic conditions will also continue challenging insurers. Earnix is proud to be at the forefront of innovation in the insurance industry, and we look forward to working with insurers to help drive the technological growth the industry is experiencing to meet the modern needs of the market."

Among the key findings from the study, are that more than two-thirds (70%) of insurers are prioritizing the deployment of AI models that make predictions based on real-time data in the next two years, while less than one-third (29%) presently have them in place. While AI is not new to insurance, the entire industry is clearly increasing its adoption. Insurers reported that they expect the impact of AI to nearly double from last year to the current year, and then more than triple in the year ahead.

Regulatory compliance is another area of focus and insurers are now investing more time on it than in years past. More than two-thirds (70%) of respondents reported they will spend more time on regulatory compliance next year compared to this year, continuing a two-year trend. The reason for the time increase may be regulatory fines, as more than half of respondents (51%) report their company had to pay a fine or issue refunds due to errors in the last year. As regulators catch up with technological advancements, new guidelines are likely to emerge, requiring insurers to continually update their frameworks. While failure to comply, will continue to become more severe.

“In today’s constantly changing landscape, it is critical for organizations to leverage AI models that provide real-time analytical data, enabling them to increase collaboration and innovation, drive product and business growth, and gain and retain market share,” said Aaron Wright, Director of Strategy at Earnix. “After years of talking about the implementation of this technology, we are finally seeing plans being put into action in this year's survey.”

About the Report

The survey, conducted by Earnix and Market Strategy Group, LLC in 2024 included 431 global insurance executives from the United States, Canada, Europe, and Australasia. Of those surveyed, 381 were from carriers with less than 20,000 employees and 50 executives from companies with more than 20,000 employees. The participants represented a range of roles and departments, including actuarial/pricing, analytics, product, underwriting, C-Suite, and IT/Technical roles.

Click here to download a full copy of the report.

About Earnix

Earnix is the premier provider of mission-critical, cloud-based intelligent solutions across pricing, underwriting, rating, and product personalization. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. Earnix has been innovating for insurers and banks since 2001, with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel.

Contact Earnix via LinkedIn, X, and Facebook. Read the Earnix blog.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104507752/en/

Contacts

Krystina Puleo
Global Director of External Communications
press@earnix.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye